Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates
-
By
-
Ekaterina I. Ryabova
-
Artem A. Derkaev
-
Ilias B. Esmagambetov
-
Mikhail A. Dovgiy
-
Ilya V. Gordeychuk
-
Inna V. Shuliakova
-
Rosa M. Hossain
-
Anton A. Blinov
-
Anna A. Iliukhina
-
Daria M. Grousova
-
Ilya D. Zorkov
-
Daria V. Avdoshina
-
Stanislav A. Gulyaev
-
Vasiliy D. Apolokhov
-
Tatiana V. Gulyaeva
-
Irina A. Favorskaya
-
Dmitry V. Shcheblyakov
-
Alexander L. Gintsburg
-
Denis Y. Logunov
-
June 4, 2026
-
0 min
3 Topic Commentaries
Intracranial Hemorrhages, Central Nervous System Infections, Machine Learning
-
Dr. Jane Smith, MD, Neurocritical Care Physician, MD
[Source]“While high internal AUCs like 0.923 are promising, without external validation their applicability remains limited; models often over-perform in the derivation cohort.”
-
Dr. Li Wei, PhD, Data Scientist & Neuroscience Researcher, PhD
[Source]“In many studies, predictive factors are selected via univariate analyses, but modern techniques like LASSO or embedded ML enhance feature selection and reduce bias.”
-
Dr. Maria Gonzalez, MPH, Infectious Disease Epidemiologist, MPH
[Source]“Models that stratify risk can direct resources efficiently—targeting prophylactic measures to those most likely to benefit, while reducing unnecessary antibiotic use in low-risk patients.”
